In this Issue:
First-line crizotinib in ALK-positive NSCLC
Thoracic radiotherapy improves survival in SCLC
Platinum-sensitivity status linked to outcomes in ES-SCLC?
Dacomitinib promising in advanced NSCLC
Identifying the lineage of lung cancer
Monitoring EGFR mutations in plasma DNA
First-line docetaxel + cisplatin for advanced NSCLC in the elderly
Cognitive impairment before and after chemotherapy
Incidence of EGFR mutation in Australian populations
Molecular profiling and targeted therapy for advanced thoracic malignancies
Please login below to download this issue (PDF)